Entera Bio Price to Free Cash Flow Ratio 2018-2021 | ENTX
Historical price to free cash flow ratio values for Entera Bio (ENTX) since 2018.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Entera Bio Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2021-10-15 |
4.52 |
|
0.00 |
| 2021-06-30 |
5.98 |
$-0.40 |
0.00 |
| 2021-03-31 |
3.81 |
$-0.52 |
0.00 |
| 2020-12-31 |
1.08 |
$-0.56 |
0.00 |
| 2020-09-30 |
1.24 |
$-0.76 |
0.00 |
| 2020-06-30 |
1.84 |
$-0.73 |
0.00 |
| 2020-03-31 |
2.06 |
$-0.71 |
0.00 |
| 2019-12-31 |
2.14 |
$-0.74 |
0.00 |
| 2019-09-30 |
2.49 |
$-0.44 |
0.00 |
| 2019-06-30 |
3.43 |
$-0.43 |
0.00 |
| 2019-03-31 |
4.33 |
$-0.80 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.107B |
$0.000B |
|
Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone for hypoparathyroidism and osteoporosis. Entera Bio Ltd. is based in Jerusalem, Israel.
|
